MCID: CRN036
MIFTS: 59

Craniopharyngioma

Categories: Rare diseases, Neuronal diseases, Endocrine diseases, Cancer diseases

Aliases & Classifications for Craniopharyngioma

MalaCards integrated aliases for Craniopharyngioma:

Name: Craniopharyngioma 12 50 56 52 42 14 69
Dysodontogenic Epithelial Tumor 50
Craniopharyngeal Duct Tumor 50
Neoplasm of Rathke's Pouch 12
Adamantinomatous Tumor 50
Rathke's Pouch Tumor 50

Characteristics:

Orphanet epidemiological data:

56
craniopharyngioma
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe),1-9/1000000 (United States),1-9/1000000 (Sweden); Age of onset: All ages;

Classifications:



Summaries for Craniopharyngioma

NIH Rare Diseases : 50 craniopharyngioma is a slow-growing benign (not cancerous) brain tumor that develops near the pituitary gland (a small endocrine gland at the base of the brain which produces several important hormones) and the hypothalamus (an endocrine organ which controls the release of hormones by the pituitary gland). this tumor most commonly affects children between 5 and 10 years of age; however, adults can sometimes be affected. although craniopharyngiomas are not cancerous, they may grow and press on nearby parts of the brain, causing symptoms including hormonal changes, vision changes, slow growth, headaches, nausea and vomiting, loss of balance, and hearing loss. the cause of these tumors is not well understood; however, researchers suspect that they begin to form during the early stages of embryo development in pregnancy (embryogenesis) and may result from metaplasia (abnormal transformation of cells). treatment for craniopharyngioma varies and may include: surgery to remove the tumor, radiation therapy, chemotherapy, and biologic therapy.  last updated: 3/31/2017

MalaCards based summary : Craniopharyngioma, also known as dysodontogenic epithelial tumor, is related to adamantinous craniopharyngioma and papillary craniopharyngioma, and has symptoms including abnormal hypothalamus morphology, cerebral calcification and intracranial cystic lesion. An important gene associated with Craniopharyngioma is CTNNB1 (Catenin Beta 1), and among its related pathways/superpathways are FoxO signaling pathway and Adipogenesis. The drugs Hydrocortisone and Prednisone have been mentioned in the context of this disorder. Affiliated tissues include brain, pituitary and hypothalamus, and related phenotypes are Increased Nanog expression and growth/size/body region

Wikipedia : 72 Craniopharyngioma is a type of brain tumor derived from pituitary gland embryonic tissue, that occurs... more...

Related Diseases for Craniopharyngioma

Diseases related to Craniopharyngioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 168)
id Related Disease Score Top Affiliating Genes
1 adamantinous craniopharyngioma 25.6 BRAF CTNNB1 GHRL GNRH1 IGF1 INS
2 papillary craniopharyngioma 12.0
3 large cell medulloblastoma 10.7 BRAF CTNNB1
4 split hand split foot nystagmus 10.6 BRAF MKI67
5 hemoglobin e disease 10.6 CTNNB1 KRT14
6 selenium poisoning 10.6 IGF1 INS
7 congenital hemolytic anemia 10.5 KRT14 KRT8
8 breast duct papilloma 10.5 KRT14 KRT8 MKI67
9 amelogenesis imperfecta local hypoplastic 10.4 KRT14 MKI67
10 trichoepithelioma, multiple familial, 1 10.4 KRT14 KRT8
11 isolated klippel-feil syndrome 10.4 POU1F1 PROP1
12 complement receptor deficiency 10.4 POU1F1 PROP1
13 urethra clear cell adenocarcinoma 10.4 KRT14 KRT8
14 lipid metabolism disorder 10.3 INS KRT14
15 complement component 8 deficiency 10.3 GNRH1 IGF1
16 periampullary adenoma 10.3 GHRL IGF1 INS
17 inherited metabolic disorder 10.3 GHRL IGF1 INS
18 obesity 10.2
19 short bowel syndrome 10.2 GHRL IGF1 INS
20 hyperlipoproteinemia, type ib 10.2 IGF1 INS
21 exostosis 10.2 GHRL IGF1 INS
22 capillary lymphangioma 10.2 GNRH1 IGF1 INS
23 grubben de cock borghgraef syndrome 10.2 GHRL IGF1 PROP1
24 bone squamous cell carcinoma 10.1 KRT14 KRT8 MMP20
25 primary hypomagnesemia 10.1 IGF1 POU1F1 PROP1
26 adenoma 10.1
27 olivopontocerebellar atrophy deafness 10.1 KRT14 KRT8
28 pituitary adenoma 10.0
29 hypoglycemic coma 10.0 GNRH1 INS TRH
30 genital dwarfism, turner type 10.0 PRL TRH
31 diabetes insipidus 10.0
32 african histoplasmosis 9.9 GNRH1 PRL
33 aortic valve atresia 9.9 PRL TRH
34 prostate leiomyoma 9.9 GNRH1 PRL
35 cerebritis 9.8
36 adenomatoid tumor 9.8 GNRH1 PRL
37 intermittent squint 9.8 GNRH1 PRL
38 lymphoepithelioma-like carcinoma 9.8 GNRH1 PRL
39 ulcerative blepharitis 9.8 IGF1 INS PRL
40 meningitis 9.8
41 germ cells tumors 9.8
42 chromosome 11p13 deletion syndrome, distal 9.8 GHRL IGF1 PRL
43 cardiovascular organ benign neoplasm 9.8 IGF1 PRL TRH
44 astrocytoma 9.8
45 hypopituitarism 9.8
46 diencephalic syndrome 9.8
47 pituitary adenoma, acth-secreting 9.7 IGF1 PRL TRH
48 childhood optic nerve glioma 9.7 BRAF CTNNB1 IGF1 PRL
49 lung cancer susceptibility 2 9.7 IGF1 INS PRL
50 neuroblastoma 9.7

Graphical network of the top 20 diseases related to Craniopharyngioma:



Diseases related to Craniopharyngioma

Symptoms & Phenotypes for Craniopharyngioma

Human phenotypes related to Craniopharyngioma:

56 32 (show all 48)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 abnormal hypothalamus morphology 56 32 obligate (100%) Obligate (100%) HP:0012286
2 cerebral calcification 56 32 hallmark (90%) Very frequent (99-80%) HP:0002514
3 intracranial cystic lesion 56 32 hallmark (90%) Very frequent (99-80%) HP:0010576
4 neoplasm of the anterior pituitary 56 32 hallmark (90%) Very frequent (99-80%) HP:0011750
5 enlarged pituitary gland 56 32 hallmark (90%) Very frequent (99-80%) HP:0012505
6 central diabetes insipidus 56 32 frequent (33%) Frequent (79-30%) HP:0000863
7 prolactin excess 56 32 frequent (33%) Frequent (79-30%) HP:0000870
8 papilledema 56 32 frequent (33%) Frequent (79-30%) HP:0001085
9 obesity 56 32 frequent (33%) Frequent (79-30%) HP:0001513
10 nausea and vomiting 56 32 frequent (33%) Frequent (79-30%) HP:0002017
11 headache 56 32 frequent (33%) Frequent (79-30%) HP:0002315
12 slow decrease in visual acuity 56 32 frequent (33%) Frequent (79-30%) HP:0007924
13 progressive visual field defects 56 32 frequent (33%) Frequent (79-30%) HP:0007987
14 pituitary hypothyroidism 56 32 frequent (33%) Frequent (79-30%) HP:0008245
15 central adrenal insufficiency 56 32 frequent (33%) Frequent (79-30%) HP:0011734
16 bitemporal hemianopia 56 32 frequent (33%) Frequent (79-30%) HP:0030521
17 abnormal visual field test 56 32 frequent (33%) Frequent (79-30%) HP:0030588
18 hydrocephalus 56 32 occasional (7.5%) Occasional (29-5%) HP:0000238
19 hearing impairment 56 32 occasional (7.5%) Occasional (29-5%) HP:0000365
20 optic atrophy 56 32 occasional (7.5%) Occasional (29-5%) HP:0000648
21 delayed puberty 56 32 occasional (7.5%) Occasional (29-5%) HP:0000823
22 increased intracranial pressure 56 32 occasional (7.5%) Occasional (29-5%) HP:0002516
23 polyphagia 56 32 occasional (7.5%) Occasional (29-5%) HP:0002591
24 cerebral ischemia 56 32 occasional (7.5%) Occasional (29-5%) HP:0002637
25 increased susceptibility to fractures 56 32 occasional (7.5%) Occasional (29-5%) HP:0002659
26 proportionate short stature 56 32 occasional (7.5%) Occasional (29-5%) HP:0003508
27 type ii diabetes mellitus 56 32 occasional (7.5%) Occasional (29-5%) HP:0005978
28 sleep apnea 56 32 occasional (7.5%) Occasional (29-5%) HP:0010535
29 sudden loss of visual acuity 56 32 very rare (1%) Very rare (<4-1%) HP:0001117
30 intellectual disability 56 32 very rare (1%) Very rare (<4-1%) HP:0001249
31 seizures 56 32 very rare (1%) Very rare (<4-1%) HP:0001250
32 coma 56 32 very rare (1%) Very rare (<4-1%) HP:0001259
33 global developmental delay 56 32 very rare (1%) Very rare (<4-1%) HP:0001263
34 myocardial infarction 56 32 very rare (1%) Very rare (<4-1%) HP:0001658
35 vertigo 56 32 very rare (1%) Very rare (<4-1%) HP:0002321
36 recurrent infections 56 32 very rare (1%) Very rare (<4-1%) HP:0002719
37 postnatal growth retardation 56 32 very rare (1%) Very rare (<4-1%) HP:0008897
38 abnormality of the nasal bone 56 32 very rare (1%) Very rare (<4-1%) HP:0010939
39 abnormality of the frontal bone 56 32 very rare (1%) Very rare (<4-1%) HP:0430000
40 hypopituitarism 56 Very frequent (99-80%)
41 hypogonadism 56 Frequent (79-30%)
42 somnolence 56 Frequent (79-30%)
43 sleep disturbance 56 Frequent (79-30%)
44 low gonadotropins (secondary hypogonadism) 56 Frequent (79-30%)
45 growth delay 56 Occasional (29-5%)
46 behavioral abnormality 56 Very rare (<4-1%)
47 hypogonadotrophic hypogonadism 32 frequent (33%) HP:0000044
48 excessive daytime somnolence 32 frequent (33%) HP:0001262

UMLS symptoms related to Craniopharyngioma:


visual disturbance

GenomeRNAi Phenotypes related to Craniopharyngioma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased Nanog expression GR00371-A-1 9.17 MCM6 MKI67 PROP1 SP7
2 Increased Nanog expression GR00371-A-3 9.17 MCM6 PROP1
3 Increased Nanog expression GR00371-A-5 9.17 PROP1

MGI Mouse Phenotypes related to Craniopharyngioma:

44 (show all 13)
id Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.27 BRAF CTNNB1 GNRH1 IGF1 INS KRT14
2 endocrine/exocrine gland MP:0005379 10.25 BRAF CTNNB1 GHRL GNRH1 IGF1 INS
3 homeostasis/metabolism MP:0005376 10.25 CTNNB1 GHRL GNRH1 IGF1 INS KRT14
4 hematopoietic system MP:0005397 10.11 BRAF CTNNB1 GNRH1 IGF1 INS KRT14
5 digestive/alimentary MP:0005381 10.07 BRAF CTNNB1 GHRL GNRH1 INS KRT14
6 immune system MP:0005387 10.06 PRL BRAF CTNNB1 GNRH1 IGF1 INS
7 integument MP:0010771 9.91 BRAF CTNNB1 GNRH1 IGF1 INS KRT14
8 hearing/vestibular/ear MP:0005377 9.88 BRAF CTNNB1 IGF1 KRT14 POU1F1
9 nervous system MP:0003631 9.81 BRAF CTNNB1 GNRH1 IGF1 INS POU1F1
10 liver/biliary system MP:0005370 9.8 PRL BRAF CTNNB1 GNRH1 INS KRT8
11 neoplasm MP:0002006 9.8 KRT14 MCM6 PRL BRAF CTNNB1 GNRH1
12 normal MP:0002873 9.56 IGF1 INS MKI67 SP7 BRAF CTNNB1
13 reproductive system MP:0005389 9.32 BRAF CTNNB1 GNRH1 IGF1 INS KRT14

Drugs & Therapeutics for Craniopharyngioma

Drugs for Craniopharyngioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 189)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754 657311
2
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
3
Butyric Acid Experimental Phase 4 107-92-6 264
4 Anesthetics Phase 4,Phase 3
5 Anti-Inflammatory Agents Phase 4,Phase 1
6 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 1
7 Cortisol succinate Phase 4
8 glucocorticoids Phase 4,Phase 1
9 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
10 Hormones Phase 4,Phase 3,Phase 2,Phase 1
11 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
12 Hydrocortisone 17-butyrate 21-propionate Phase 4
13 Hydrocortisone acetate Phase 4
14 Hydrocortisone-17-butyrate Phase 4
15
Diazoxide Approved Phase 3,Phase 2 364-98-7 3019
16
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
17
Donepezil Approved Phase 3,Phase 2,Early Phase 1 120014-06-4 3152
18
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
19
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 1 50-02-2 5743
20
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
21
Ondansetron Approved Phase 3 99614-02-5 4595
22
Exenatide Approved, Investigational Phase 3,Phase 2,Phase 1 141758-74-9 15991534
23 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
24 Liver Extracts Phase 3,Phase 1,Phase 2
25 Antihypertensive Agents Phase 3,Phase 2
26 Vasodilator Agents Phase 3,Phase 2
27 Adjuvants, Anesthesia Phase 3
28 Analgesics Phase 3
29 Analgesics, Opioid Phase 3
30 Anesthetics, General Phase 3
31 Anesthetics, Intravenous Phase 3
32 Central Nervous System Depressants Phase 3,Phase 1
33 Narcotics Phase 3
34 Peripheral Nervous System Agents Phase 3,Phase 1
35 Cholinergic Agents Phase 3,Phase 2,Early Phase 1
36 Cholinesterase Inhibitors Phase 3,Phase 2,Early Phase 1
37 Neurotransmitter Agents Phase 3,Phase 2,Phase 1,Early Phase 1
38 Nootropic Agents Phase 3,Phase 2,Early Phase 1
39 Antiemetics Phase 3,Phase 1
40 Autonomic Agents Phase 3,Phase 1
41 BB 1101 Phase 3,Phase 1
42 Dexamethasone acetate Phase 3,Phase 1 1177-87-3
43 Emetics Phase 3
44 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
45 Hypoglycemic Agents Phase 3,Phase 2,Phase 1
46 Incretins Phase 3,Phase 2,Phase 1
47 glucagon Phase 3
48 Glucagon-Like Peptide 1 Phase 3
49 Cola Nutraceutical Phase 3,Phase 1
50
Lenograstim Approved Phase 1, Phase 2 135968-09-1

Interventional clinical trials:

(show top 50) (show all 102)

id Name Status NCT ID Phase Drugs
1 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4 Hydrocortisone;Prednisone
2 SCRT Versus Conventional RT in Children and Young Adults With Low Grade and Benign Brain Tumors Unknown status NCT00517959 Phase 3
3 Effect of Diazoxide on the Obesity Secondary to Hypothalamic-pituitary Lesions Completed NCT00306683 Phase 3 DIAZOXIDE
4 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
5 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
6 Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
7 Energy Balance & Weight Loss in Craniopharyngioma-related Hypothalamic Obesity Recruiting NCT02664441 Phase 3 Exenatide;placebo
8 90Yttrium Colloid for the Treatment of Cystic Sellar/Parasellar Tumors Recruiting NCT02081768 Phase 3
9 Multicentre Double-blind Randomized Clinical Trial Assessing Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy Not yet recruiting NCT02860923 Phase 3 Exenatide;Placebo
10 Hypothalamic Obesity Following Craniopharyngioma Surgery: A Pilot Trial of Combined Metformin and Diazoxide Therapy Completed NCT00892073 Phase 2 Diazoxide;Metformin
11 Weight Loss Study for Patients With Obesity Due to Craniopharyngioma or Other Brain Tumor Completed NCT01484873 Phase 2 Exenatide
12 A Study for Image-Guided Radiation Therapy in Pediatric Brain Tumors and Side Effects Completed NCT00187226 Phase 2
13 An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic Injury Completed NCT02063295 Phase 2 ZGN-440 sterile diluent;ZGN-440 for injectable suspension
14 Irinotecan in Treating Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
15 Antineoplaston Therapy in Treating Children With Brain Tumors Completed NCT00003458 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
16 Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid Tumors Completed NCT00005952 Phase 1, Phase 2 temozolomide
17 Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Tumors Completed NCT00003461 Phase 1, Phase 2
18 Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma Completed NCT00006102 Phase 2 becatecarin
19 Temozolomide Followed by Radiation Therapy in Treating Children With Newly Diagnosed Malignant CNS Tumors Completed NCT00005955 Phase 2 temozolomide
20 Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor Completed NCT00070161 Phase 2 donepezil hydrochloride
21 Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment Completed NCT00066248 Phase 2 cyproheptadine hydrochloride;megestrol acetate
22 A Phase II Trial of Intensity-Modulated Proton Therapy for Incompletely Resected Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection Recruiting NCT02792582 Phase 2
23 Peginterferon Alfa-2b in Treating Younger Patients With Craniopharyngioma That is Recurrent or Cannot Be Removed By Surgery Recruiting NCT01964300 Phase 2
24 Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma Recruiting NCT03224767 Phase 2 Vemurafenib;Cobimetinib
25 Intranasal Oxytocin in Hypothalamic Obesity Recruiting NCT02849743 Phase 2 Syntocinon;Placebo (for Syntocinon)
26 Dabrafenib in Treating Patients With BRAF Mutated Ameloblastoma Recruiting NCT02367859 Phase 2 Dabrafenib
27 Methionine PET/CT Studies In Patients With Cancer Recruiting NCT00840047 Phase 2 Methionine
28 Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas Recruiting NCT01966809 Phase 2 Photofrin photodynamic therapy.
29 A Phase II Trial of Limited Surgery and Proton Therapy for Craniopharyngioma or Observation After Radical Resection Active, not recruiting NCT01419067 Phase 2 ^1^8F-fluorodeoxyglucose;^1^1C-methionine
30 Management of Pediatric Craniopharyngioma by a Combination of Partial Surgical Resection, and Protontherapy (Craniopharyngioma) Active, not recruiting NCT02842723 Phase 2
31 Effects of Exenatide on Hypothalamic Obesity Active, not recruiting NCT01061775 Phase 1, Phase 2 Exenatide
32 Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Active, not recruiting NCT00939770 Phase 1, Phase 2 crizotinib
33 Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Active, not recruiting NCT00788125 Phase 1, Phase 2 carboplatin;dasatinib;etoposide phosphate;ifosfamide
34 Methylphenidate HCl or Modafinil in Treating Young Patients With Excessive Daytime Sleepiness After Cancer Therapy Terminated NCT01348607 Phase 2 methylphenidate hydrochloride;modafinil;placebo
35 Tumor Classification and Its Application in Surgical Treatment of Craniopharyngioma Unknown status NCT00949156 Phase 1
36 Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors Unknown status NCT00002647 Phase 1 verteporfin
37 Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors Unknown status NCT00007813 Phase 1 carboplatin;cyclophosphamide;etoposide
38 Erlotinib Alone or in Combination With Radiation Therapy in Treating Young Patients With Refractory or Relapsed Malignant Brain Tumors or Newly Diagnosed Brain Stem Glioma Unknown status NCT00360854 Phase 1 erlotinib hydrochloride
39 Stereotactic Radiosurgery in Treating Patients With Brain Tumors Completed NCT00019578 Phase 1
40 Cilengitide in Treating Children With Refractory Primary Brain Tumors Completed NCT00063973 Phase 1 cilengitide
41 Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors Completed NCT00052780 Phase 1 O6-benzylguanine;temozolomide
42 ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors Completed NCT00946335 Phase 1 veliparib;temozolomide
43 Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma Completed NCT00363272 Phase 1 ispinesib
44 Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors Completed NCT00100880 Phase 1 lenalidomide
45 FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia Completed NCT00053963 Phase 1 romidepsin
46 RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma Completed NCT01119599 Phase 1 Gamma-Secretase Inhibitor RO4929097;Temozolomide
47 Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors Completed NCT01076530 Phase 1 vorinostat;temozolomide
48 Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma Completed NCT00994500 Phase 1 vorinostat;bortezomib
49 SCH 66336 in Treating Children With Recurrent or Progressive Brain Tumors Completed NCT00015899 Phase 1 lonafarnib
50 O6-benzylguanine and Carmustine in Treating Children With Refractory CNS Tumors Completed NCT00003765 Phase 1 O6-benzylguanine;carmustine

Search NIH Clinical Center for Craniopharyngioma

Cochrane evidence based reviews: craniopharyngioma

Genetic Tests for Craniopharyngioma

Anatomical Context for Craniopharyngioma

MalaCards organs/tissues related to Craniopharyngioma:

39
Brain, Pituitary, Hypothalamus, Bone, Testes, T Cells, Liver

Publications for Craniopharyngioma

Articles related to Craniopharyngioma:

(show top 50) (show all 754)
id Title Authors Year
1
Recent advances in molecular pathology of craniopharyngioma. ( 28781761 )
2017
2
Endocrine Disorders Developing after Surgical Intervention of Craniopharyngioma in Children. ( 28508600 )
2017
3
Spontaneous intraventricular rupture of a craniopharyngioma cyst: A case report. ( 28660168 )
2017
4
Predictors of visual outcome in patients operated for craniopharyngioma - a Danish national study. ( 28661562 )
2017
5
Intracystic interferon-alpha in pediatric craniopharyngioma patients: an international multicenter assessment on behalf of SIOPE and ISPN. ( 28499018 )
2017
6
Norman M. Dott, master of hypothalamic craniopharyngioma surgery: the decisive mentoring of Harvey Cushing and Percival Bailey at Peter Bent Brigham Hospital. ( 28059655 )
2017
7
BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors. ( 28425764 )
2017
8
Proteomics in pediatric cystic craniopharyngioma. ( 28414889 )
2017
9
Child dermoid cyst mimicking a craniopharyngioma: the benefit of MRI T2-weighted diffusion sequence. ( 28921047 )
2017
10
Malignant Transformation of Craniopharyngioma without Radiation Therapy: Case Report and Review of the Literature. ( 28061501 )
2017
11
Genetically engineered mouse models of craniopharyngioma: an opportunity for therapy development and understanding of tumor biology. ( 28414891 )
2017
12
Intracystic interferon-alpha in pediatric craniopharyngioma patients. ( 28922862 )
2017
13
Models of human adamantinomatous craniopharyngioma tissue: Steps toward an effective adjuvant treatment. ( 28414888 )
2017
14
The purine receptor P2X7R regulates the release of pro-inflammatory cytokines in human craniopharyngioma. ( 28389503 )
2017
15
Interleukina896 induces an epitheliala89mesenchymal transition phenotype in human adamantinomatous craniopharyngioma cells and promotes tumor cell migration. ( 28487953 )
2017
16
Anorexia-cachexia syndrome-like hypothalamic neuroendocrine dysfunction in a patient with a papillary craniopharyngioma. ( 28469924 )
2017
17
Primary Ectopic Ethmoidal Craniopharyngioma. ( 28403130 )
2017
18
Treatment of Cystic Craniopharyngioma with Intracystic Stereotactic Instillation of Phosphorus 32. ( 28883874 )
2017
19
Molecular Analyses Reveal Inflammatory Mediators in the Solid Component and Cyst Fluid of Human Adamantinomatous Craniopharyngioma. ( 28859336 )
2017
20
In Reply to "Craniopharyngioma: Surgical Outcome as Related to the Degree of Hypothalamic Involvement". ( 28732411 )
2017
21
Anatomic dissection of arachnoid membranes encircling the pituitary stalk on fresh non formalin fixed specimens: anatomo-radiologic correlations and clinical applications in craniopharyngioma surgery. ( 28774763 )
2017
22
Do craniopharyngioma molecular signatures correlate with clinical characteristics? ( 28707994 )
2017
23
Recurrent papillary craniopharyngioma with BRAFV600E mutation treated with neoadjuvant-targeted therapy. ( 28918496 )
2017
24
Hypothalamic obesity after craniopharyngioma surgery: Treatment with a long acting glucagon like peptide 1 derivated. ( 28440760 )
2017
25
Confounding features of ectopic craniopharyngioma: A differential for tumors showing diffusion restriction. ( 28413554 )
2017
26
Microstructure alterations in the Hypothalamus in cranially radiated Childhood Leukemia survivors but not in Craniopharyngioma patients unaffected by hypothalamic damage. ( 28502079 )
2017
27
Psychological well-being and independent living of young adults with childhood-onset craniopharyngioma. ( 28485516 )
2017
28
Preclinical transgenic and patient-derived xenograft models recapitulate the radiological features of human adamantinomatous craniopharyngioma. ( 28481062 )
2017
29
Multi-modality, Multi-directional Resection of Craniopharyngioma: versatility in alternating the principal and auxiliary surgical corridors and visualization modalities. ( 28344177 )
2017
30
Intracystic interferon-alpha in pediatric craniopharyngioma patients-reply. ( 28922866 )
2017
31
Genomic Alterations of Adamantinomatous and Papillary Craniopharyngioma. ( 28069929 )
2017
32
Spontaneous Intra-Parenchymal Rupture of Craniopharyngioma - A Rare Phenomenon. ( 28893008 )
2017
33
Sphenoid wing en plaque meningioma development following craniopharyngioma surgery and radiotherapy: Radiation-induced after three decades. ( 28761508 )
2017
34
The neuroendocrine sequelae of paediatric craniopharyngioma: a 40 year meta-data analysis of 185 cases from three UK centres. ( 28073908 )
2017
35
Review of management and morbidity of pediatric craniopharyngioma patients in a low-middle-income country: a 12-year experience. ( 28455541 )
2017
36
MAPK pathway activation in the embryonic pituitary results in stem cell compartment expansion, differentiation defects and provides insights into the pathogenesis of papillary craniopharyngioma. ( 28506993 )
2017
37
The metabolic syndrome and its components in 178 patients treated for craniopharyngioma after 16 years of follow-up. ( 28882980 )
2017
38
Recovery from diabetes insipidus and preservation of thyroid function after craniopharyngioma removal and pituitary stalk sectioning. ( 28917091 )
2017
39
Effect of Preserving the Pituitary Stalk During Resection of Craniopharyngioma in Children on the Diabetes Insipidus and Relapse Rates and Long-Term Outcomes. ( 28749844 )
2017
40
Craniopharyngioma: Surgical Outcome as Related to the Degree of Hypothalamic Involvement. ( 28732410 )
2017
41
Papillary craniopharyngioma: A clinicopathologic study of a rare entity from a major tertiary care center in Pakistan. ( 28488624 )
2017
42
A quantitative analysis of craniopharyngioma cyst expansion during and after radiation therapy and surgical implications. ( 27903114 )
2016
43
Periostin activates pathways involved in epithelial-mesenchymal transition in adamantinomatous craniopharyngioma. ( 26723972 )
2016
44
Investigating the Role of Hypothalamic Tumor Involvement in Sleep and Cognitive Outcomes Among Children Treated for Craniopharyngioma. ( 27189690 )
2016
45
Visualization of 90Yttrium Colloid Within a Cystic Craniopharyngioma Using PET/CT/MRI Fusion. ( 27846921 )
2016
46
Ectopic craniopharyngioma of the fourth ventricle in a patient with Gardner syndrome. ( 26995577 )
2016
47
Molecular pathology of adamantinomatous craniopharyngioma: review and opportunities for practice. ( 27903120 )
2016
48
Expanded Endonasal Endoscopic Approach for Resection of an Infrasellar Craniopharyngioma. ( 27554305 )
2016
49
Atypical teratoid/rhabdoid tumour following craniopharyngioma radiotherapy during childhood. ( 27461272 )
2016
50
Risk-adapted treatment and follow-up management in childhood-onset craniopharyngioma. ( 26982163 )
2016

Variations for Craniopharyngioma

ClinVar genetic disease variations for Craniopharyngioma:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 CTNNB1 NM_001904.3(CTNNB1): c.94G> T (p.Asp32Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs28931588 GRCh37 Chromosome 3, 41266097: 41266097
2 CTNNB1 NM_001904.3(CTNNB1): c.100G> A (p.Gly34Arg) single nucleotide variant Likely pathogenic rs121913399 GRCh37 Chromosome 3, 41266103: 41266103
3 CTNNB1 NM_001904.3(CTNNB1): c.100G> C (p.Gly34Arg) single nucleotide variant Likely pathogenic rs121913399 GRCh37 Chromosome 3, 41266103: 41266103

Cosmic variations for Craniopharyngioma:

9 (show all 22)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM5672 CTNNB1 pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.94G>A p.D32N 8
2 COSM5676 CTNNB1 pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.122C>T p.T41I 8
3 COSM5669 CTNNB1 pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.98C>T p.S33F 8
4 COSM5673 CTNNB1 pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.98C>A p.S33Y 8
5 COSM5679 CTNNB1 pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.110C>G p.S37C 8
6 COSM5662 CTNNB1 pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.110C>T p.S37F 8
7 COSM5701 CTNNB1 pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.122C>G p.T41S 8
8 COSM5758 CTNNB1 pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.127G>A p.A43T 8
9 COSM5677 CTNNB1 pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.98C>G p.S33C 8
10 COSM5687 CTNNB1 pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.109T>C p.S37P 8
11 COSM5668 CTNNB1 pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.94G>C p.D32H 8
12 COSM5683 CTNNB1 pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.97T>G p.S33A 8
13 COSM5682 CTNNB1 pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.97T>C p.S33P 8
14 COSM5686 CTNNB1 pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.100G>A p.G34R 8
15 COSM5684 CTNNB1 pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.100G>C p.G34R 8
16 COSM5661 CTNNB1 pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.94G>T p.D32Y 8
17 COSM5674 CTNNB1 pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.104T>G p.I35S 8
18 COSM5691 CTNNB1 pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.95A>T p.D32V 8
19 COSM5681 CTNNB1 pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.95A>G p.D32G 8
20 COSM5663 CTNNB1 pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.133T>C p.S45P 8
21 COSM5664 CTNNB1 pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.121A>G p.T41A 8
22 COSM476 BRAF pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.1799T>A p.V600E 8

Expression for Craniopharyngioma

Search GEO for disease gene expression data for Craniopharyngioma.

Pathways for Craniopharyngioma

GO Terms for Craniopharyngioma

Cellular components related to Craniopharyngioma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 endosome lumen GO:0031904 8.96 INS PRL
2 cell periphery GO:0071944 8.8 CTNNB1 KRT14 KRT8

Biological processes related to Craniopharyngioma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cell proliferation GO:0008283 9.78 CTNNB1 IGF1 MKI67 PRL
2 negative regulation of apoptotic process GO:0043066 9.65 BRAF GHRL GNRH1 IGF1 PROP1
3 response to organic cyclic compound GO:0014070 9.63 GNRH1 MKI67 TRH
4 positive regulation of MAPK cascade GO:0043410 9.5 CTNNB1 IGF1 INS
5 positive regulation of glycolytic process GO:0045821 9.43 IGF1 INS
6 cell fate specification GO:0001708 9.4 CTNNB1 POU1F1
7 positive regulation of glycogen biosynthetic process GO:0045725 9.37 IGF1 INS
8 adenohypophysis development GO:0021984 9.16 POU1F1 PROP1
9 negative regulation of feeding behavior GO:2000252 8.96 INS TRH
10 somatotropin secreting cell differentiation GO:0060126 8.62 POU1F1 PROP1

Molecular functions related to Craniopharyngioma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.1 GHRL GNRH1 IGF1 INS PRL TRH
2 insulin-like growth factor receptor binding GO:0005159 8.96 IGF1 INS

Sources for Craniopharyngioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....